Blood-Thinning Medicine After a Coronary Stent: Why Taking It Exactly as Prescribed Matters

The discharge bag is heavier than expected. Inside it, beside the leaflet with the cartoon heart and the appointment card, sit the boxes that will shape the next year: the blood thinners after coronary stent placement that the nurse mentioned three times before signing the paperwork. Three times, because she knows what tends to happen at week six, when the chest feels fine, the bruises on the forearm have faded, and a person starts to wonder whether all of this is still necessary.

It is a fair question, and it deserves a proper answer rather than a warning. The stent that now props open a coronary artery is a small mesh tube, thinner than a pencil lead, and the body has not yet decided what to make of it. Until it has, a few tablets stand between that mesh and the clotting system that spent millions of years learning to seal any foreign surface it finds.

This explainer walks through why those medicines exist, how long they are usually taken, what the first weeks feel like, and where the real risks lie. The decisions belong to your treating team. The understanding can belong to you.

What blood thinners after coronary stent placement actually do

Start with a small correction to the phrase itself. Most of what patients call blood thinners after a coronary stent do not thin the blood at all. They are antiplatelet medicines, a class that makes platelets, the tiny cell fragments that start every clot, less sticky. Blood keeps its normal thickness; it simply loses some of its eagerness to plug a gap.

Platelets work like emergency crews. When they meet a damaged vessel wall, a rough surface, or a foreign material, they change shape, release chemical signals, and pull in neighbors until a plug forms. On a scraped knee that is exactly what you want. Inside a coronary artery that has just been stretched by a balloon and lined with metal, the same reflex can seal the vessel shut within minutes.

Two medicines usually share the job, which is why the approach is called dual antiplatelet therapy. Aspirin blocks an enzyme called cyclooxygenase, cutting off one of the signals platelets use to recruit each other. The second medicine, from a group known as P2Y12 inhibitors (generics include clopidogrel, ticagrelor and prasugrel), blocks a different receptor on the platelet surface so that a second recruitment signal also goes unanswered. MedlinePlus describes this pairing as the standard approach after stent placement precisely because the two mechanisms cover each other’s gaps.

The effect is not switch-like. Platelets live roughly seven to ten days, and each medicine works on the platelets present at the time. Stop taking one and, over about a week, a fresh population of fully functional platelets replaces the blunted ones. That slow return is why a single missed day is unlikely to be catastrophic, and also why stopping for a week or more is a different matter entirely.

Nothing in this arrangement repairs the artery. The medicines buy time while the body does the actual repair work, which brings us to the stent itself.

Why a new stent needs protection while the artery heals

A coronary stent is a tube of fine metal mesh, expanded inside a narrowed artery to hold it open after the fatty plaque has been pressed against the wall. Most stents used today are drug-eluting, meaning the mesh is coated with a slow-release medicine that discourages scar tissue from growing back into the channel. That coating is the reason modern stents stay open longer than the bare-metal versions of earlier decades, as Mayo Clinic notes, but it comes with a trade-off.

The inside of every healthy artery is lined with a single layer of cells called the endothelium. This lining is what tells passing platelets to relax and keep moving. When a stent is placed, the balloon inflation cracks the plaque and bruises that lining, and the metal struts sit exposed to flowing blood. The body’s response is to grow new endothelium over the struts, a process sometimes called endothelialization. Once the mesh is fully covered, blood no longer sees metal; it sees vessel wall, and the clotting reflex calms down.

Here is the trade-off. The very coating that stops scar tissue from choking the stent also slows the healthy lining from covering the struts. Bare metal might be sealed within weeks; a drug-eluting stent can take months to reach the same point. During that window, every strut is a potential anchor for a platelet plug.

A clot forming inside the stent is called stent thrombosis. It is uncommon on dual antiplatelet therapy and considerably more likely when the medicines are stopped early, which is why guideline bodies cited by the American Heart Association treat premature discontinuation as one of the strongest avoidable risk factors after stenting. When it happens, the artery that was opened yesterday or last month can block completely, producing a heart attack that is often larger than the original problem, because the vessel had been fully open and the heart muscle downstream had no time to develop alternative supply.

Antiplatelet vs anticoagulant: what is the difference?

Confusion between these two groups causes real problems, including patients who stop one medicine because they believe it duplicates another. The distinction is worth two minutes.

Antiplatelet medicines, as described above, act on platelets. They are the frontline treatment after a coronary stent because platelet clumping on the metal surface is the main threat. Aspirin and the P2Y12 inhibitors belong here.

Anticoagulants act on a separate system: the cascade of clotting proteins in the plasma that weaves a fibrin mesh around a platelet plug and turns it into a stable clot. Warfarin, an older medicine that interferes with vitamin K, and the newer direct oral anticoagulants (sometimes abbreviated DOACs) belong to this group. The American Heart Association groups both families under the broader heading of anti-clotting agents, but their jobs are different. Anticoagulants are prescribed mainly for clots that form in slow-moving or turbulent blood: in the heart chambers during atrial fibrillation, in leg veins, or around some artificial heart valves.

A person can need both. Someone with atrial fibrillation who has just received a stent may leave hospital on an anticoagulant plus one or two antiplatelet medicines, a combination sometimes called triple therapy. Because bleeding risk climbs with each added agent, cardiology teams usually keep such combinations as short as the stent allows and then step down, following pathways described in professional guidelines. The exact plan is highly individual.

Why does the difference matter to you at the kitchen table? Because an anticoagulant does not protect a stent the way an antiplatelet does, and an antiplatelet does not protect against the clots atrial fibrillation produces. Neither is a substitute for the other. If your medicine list contains items from both groups, each one is there for a distinct reason, and any question about whether one has become redundant belongs to the prescriber, not to the medicine cabinet.

How long is dual antiplatelet therapy after a stent?

This is the question everyone asks, and the honest answer has two parts: a typical range, and a reason the range is wide.

The NHS advises that after coronary angioplasty with a stent, most people continue the second antiplatelet medicine for up to about 12 months, with the longer end of that range usual when the stent was placed during a heart attack. Mayo Clinic describes the same pattern: aspirin generally continues long term, while the second medicine is commonly taken for around six to 12 months, with the exact duration set by the cardiologist. These are typical windows, not promises, and they shift with the individual.

The reason for the spread lies in balancing two risks that pull in opposite directions. Clotting risk is highest in the early months and falls as the stent seals over. Bleeding risk from the medicines stays roughly constant for as long as they are taken, and rises with age, kidney disease, prior bleeding, or certain other medicines. The cardiology team weighs those curves against each other for each patient.

Situation at the time of stenting	Medicines typically involved (by class)	Typical duration of the second antiplatelet	Source
Stent placed during a heart attack	Aspirin plus a P2Y12 inhibitor	Commonly up to around 12 months	NHS
Stent placed for stable angina (planned procedure)	Aspirin plus a P2Y12 inhibitor	Often shorter, commonly in the range of six to 12 months	Mayo Clinic
Any stent, with high bleeding risk	Aspirin plus a P2Y12 inhibitor, sometimes stepped down early	Individualized; may be shortened by the team	Mayo Clinic
Any stent, with atrial fibrillation	Anticoagulant plus antiplatelet(s), then stepped down	Individualized; combination kept as brief as safe	AHA

Aspirin sits outside this table because, for most people with coronary artery disease, it continues indefinitely rather than for a set term. The table describes the second medicine, which is the one people most often wonder about stopping.

Who is usually prescribed longer, and who is asked to wait or stop sooner

Two people can receive the same stent in the same artery on the same afternoon and leave with different plans. That is not inconsistency; it is the plan doing its job.

Longer courses of the second antiplatelet tend to be considered when the clotting side of the scale is heavier. Common reasons include a stent placed during a heart attack rather than a planned procedure, several stents or long segments of stented artery, stents in branching points or in a vessel supplying a large portion of heart muscle, diabetes, chronic kidney disease, or a previous episode of stent thrombosis. In some of these situations a cardiologist may discuss continuing the second medicine beyond the first year, a decision guideline bodies leave to case-by-case judgement.

Shorter courses, or an earlier step down to a single antiplatelet, tend to be considered when the bleeding side is heavier: a history of gastrointestinal bleeding, anemia, older age combined with frailty, liver or kidney disease, a need for an anticoagulant as well, or a planned operation that cannot be delayed. Modern drug-eluting stents seal more predictably than older designs, which is part of why guidelines now allow more flexibility to shorten therapy for people at high bleeding risk.

Who is asked to wait? Occasionally the waiting concerns the stent itself. A person who needs major non-cardiac surgery within the next few months, for example, may be offered a different strategy or a delay so that the surgery does not fall in the window when interrupting antiplatelet therapy is most dangerous. Someone with an active bleeding problem may have the stent procedure timed around treating that first.

What the categories share is that they are set before or immediately after the procedure, by people who can see the angiogram and the blood results. A feeling of wellness at week six is not one of the variables, and neither is a friend’s experience with a different stent in a different artery. If your circumstances change, that is a conversation to have, not an adjustment to make.

What happens if you miss doses or stop blood thinners after a coronary stent early

The failure mode is specific, and it is worth describing plainly rather than vaguely.

When antiplatelet cover falls away before the stent has sealed over, platelets encounter exposed struts and do what platelets do. The plug that forms can grow within minutes into a clot that fills the stent. Because the artery was fully open before, blood flow stops abruptly rather than gradually, and the heart muscle downstream has had no reason to build collateral vessels. The result is usually a sudden heart attack, frequently a large one. The American Heart Association lists stopping antiplatelet therapy early as a leading cause of this complication.

Timing matters. The risk is highest in the first weeks after the procedure and falls steadily as endothelium covers the metal. Stopping the second medicine at month two carries a different weight from stopping it at month eleven, which is one reason the team may be more comfortable with a planned interruption late in the course than an unplanned one early on.

A single missed dose is a different situation from stopping. Because platelet inhibition wears off over days rather than hours, one forgotten tablet does not immediately strip away protection. The correct response to a missed dose depends on the medicine and how late you realise, so the safe approach is to follow the written instructions from your pharmacy or ask the prescribing team rather than improvising. Repeated misses are where the danger accumulates, because each gap lets a portion of the platelet population recover.

The scenarios that most often lead to early stopping are mundane: a prescription running out over a holiday weekend, a bout of stomach upset blamed on the medicine, a dentist or surgeon asking whether it could be paused, or plain fatigue with the routine. None of these are reasons to stop on your own. Each is a reason to contact the cardiology team, who can usually solve the practical problem without exposing the stent.

What the first days and weeks on blood thinners after a coronary stent usually look like

Most people go home the same day or the day after a planned stent, and within a few days after one placed during a heart attack, according to NHS recovery guidance. The medicines start in hospital, often with a larger first dose given by the team before or during the procedure, so that platelet inhibition is already in place when the stent goes in. By the time you are packing the discharge bag, the routine has begun.

The first week is mostly about the access site. Whether the catheter went in through the wrist or the groin, a bruise is expected and can look alarming as it spreads and changes color. Antiplatelet medicines make bruises larger and slower to fade than they would otherwise be. A firm lump that grows, or bleeding that does not stop with steady pressure, is a reason to seek care; a purple patch that yellows over ten days is not.

Weeks two to four bring the small annoyances. Nosebleeds that last a little longer. Gums that bleed when you floss. A shaving nick that needs a tissue for several minutes rather than one. Some people notice more bruises on the arms and legs from knocks they do not remember. These are the everyday cost of blunted platelets, and while they are worth mentioning at the follow-up appointment, they rarely change the plan.

Some P2Y12 inhibitors produce breathlessness in a minority of people, usually early and often easing over weeks; it should still be reported, because breathlessness after a stent has other possible causes that need ruling out. Indigestion is common with aspirin, and the team may add a stomach-protecting medicine rather than remove the aspirin.

By month two or three the routine is usually invisible, which is exactly when it becomes easy to neglect. Pairing the tablets with a fixed daily anchor, such as brushing your teeth, and keeping a spare week of supply on hand are the low-drama habits that carry most people through to the follow-up where duration is reviewed.

Bleeding, bruising and other side effects: what is expected and what is not

Every medicine that dampens clotting trades one risk for another, and honesty about the bleeding side helps people stay the course rather than quietly stopping.

Minor bleeding is common and expected. Bruises appear more easily and last longer. Small cuts take longer to stop. Gums bleed with brushing. Periods may be heavier for those who have them. None of these mean the medicine is doing harm; they are visible evidence that it is doing what it was prescribed to do. Cleveland Clinic and MedlinePlus both list these as the usual accompaniments of antiplatelet therapy.

Moderate bleeding deserves a call rather than a shrug. Nosebleeds that last more than a brief episode or recur daily, blood in the urine, unusually heavy periods, or bruises appearing without any knock at all should be discussed with the team. Often the response is a check of blood counts and kidney function, or a review of other medicines that might be adding to the effect. The plan may or may not change; the point is that a professional makes that call.

Serious bleeding is uncommon but not rare, and it is the main reason the second antiplatelet is time-limited rather than lifelong. Bleeding in the stomach or bowel is the most frequent serious form. Aspirin in particular can irritate the stomach lining, which is why many people are also prescribed a medicine that reduces stomach acid for the duration of dual therapy. Bleeding inside the skull is the rarest and most feared form and is a large part of why bleeding-risk factors weigh so heavily in duration decisions.

Beyond bleeding, the second medicine can occasionally cause rash, breathlessness (as noted above), or, very rarely, a drop in certain blood cells. Any new symptom that arrives after a medicine change is worth a conversation. What is not helpful is stopping the medicine to see whether the symptom resolves; the stent does not participate in that experiment safely.

Stopping clopidogrel after a stent for dental work or surgery: why you never decide alone

Sooner or later, someone with a clipboard will ask whether the medicine can be stopped. Perhaps a dentist before an extraction, a surgeon before a hernia repair, or an endoscopy unit before a colonoscopy. The instinct to say yes, to be helpful, is strong. Resist it long enough to make one phone call.

Most dental procedures, including extractions and cleanings, can be carried out without stopping antiplatelet medicines, according to NHS and professional dental guidance; local measures such as pressure, sutures and gauze control the bleeding, and the risk of stopping outweighs the inconvenience of a longer-oozing socket. Dentists who work with heart patients know this and will often proceed with precautions rather than requesting an interruption.

Surgery is more nuanced, and this is where the cardiology team must be in the conversation. If an operation can be postponed until the second antiplatelet has completed its planned course, that is often the safest path. If it cannot, the cardiologist and surgeon jointly decide which medicines to continue, which to pause, how far in advance, and how quickly to restart afterwards. Aspirin is frequently continued through surgery because the bleeding it adds is modest compared with the protection it provides; the second medicine is the one more often paused, and even then for the shortest interval the stent allows.

The critical detail is who initiates the pause. A patient who stops the medicine because a receptionist mentioned it, or because a pre-operative leaflet written for the general population says to, has taken a decision that properly belongs to two specialists comparing notes. Ask the surgical team to contact your cardiology team directly, or bring the cardiology team’s written advice to the pre-operative assessment. Carry a card or a note in your wallet stating that you have a coronary stent and take antiplatelet medicine, so that this conversation happens even if you are unable to start it yourself.

Aspirin after a heart stent: why the smallest tablet still matters

Aspirin has a familiarity problem. It sits in bathroom cabinets next to the plasters, sold without a prescription, taken for headaches. That familiarity leads some people to treat the aspirin on their heart medicine list as optional, or to assume that the stronger-sounding second medicine is doing the real work. Both assumptions are wrong.

For someone with coronary artery disease, aspirin is usually the medicine that continues after the second antiplatelet has finished, and for most people it continues indefinitely, as Mayo Clinic and the NHS both describe. Its job is not only to protect the stent in the early months but to protect the rest of the coronary arteries, which have the same disease process at work even where no stent was placed. Plaques elsewhere can crack; platelets can pile onto the crack; aspirin blunts that response for as long as it is taken.

The dose used for heart protection is much lower than the dose used for pain, and it is not something to adjust by reaching for the household bottle. Taking extra does not add protection and does add stomach irritation and bleeding risk. Taking a pain-relief dose for a headache while also on the heart dose is a question for the pharmacist, not a guess.

Some people cannot take aspirin, because of true allergy, severe asthma triggered by it, or a history of bleeding ulcers that recur despite stomach protection. In those situations the cardiology team chooses an alternative long-term antiplatelet strategy. What they do not do is leave the patient with nothing, which is the outcome when someone decides independently that the little tablet is not worth the bother.

Think of the two medicines as a pair working different shifts. The second antiplatelet covers the high-risk early period and then clocks off. Aspirin covers the long shift that follows, quietly, for years. Neglecting it because it looks ordinary is one of the more avoidable mistakes in cardiology.

Which medicines, supplements and foods interact with stent blood thinners?

The medicines protecting a stent are sensitive to company. Some interactions increase bleeding; a smaller number can quietly reduce the protection. Knowing the categories helps you ask the right questions.

Non-steroidal anti-inflammatory drugs, the group that includes ibuprofen and naproxen, are the most common troublemakers. Taken alongside antiplatelet medicines they add stomach irritation and bleeding risk, and some can interfere with aspirin’s action on platelets. Many people reach for them without a second thought for back pain or a sore knee. For someone with a stent, the pharmacist should be consulted first; alternatives usually exist.

Certain stomach-acid medicines were once thought to blunt the effect of clopidogrel, which is processed in the liver into its active form. Current evidence is mixed, and cardiology teams often prefer particular agents within the class when both are needed. This is a well-known consideration; you do not need to manage it yourself, but it is a good example of why the full medicine list should sit in front of whoever prescribes anything new.

Supplements deserve the same scrutiny. Fish oil, ginkgo, garlic extracts, high-dose vitamin E and turmeric are among those with reported antiplatelet or bleeding effects. The NIH Office of Dietary Supplements notes these interactions for several of them. The evidence for most is modest, but the direction is consistent, and the combination is rarely necessary. Mention every supplement, including the ones that seem trivial.

Alcohol in larger amounts irritates the stomach lining and impairs clotting on its own, compounding aspirin’s effect. Moderate intake is a conversation with the team rather than an absolute rule, but binges are unwise while on dual therapy.

Diet matters less for antiplatelet medicines than for warfarin, whose vitamin K interactions are well known. If your list includes an anticoagulant as well, dietary advice specific to that medicine will apply and should come from your prescriber or pharmacist.

What people often get wrong about blood thinners and stents

Some myths are harmless. These are not.

Myth: once the stent is in, the artery is fixed. The stent holds one narrowed segment open. It does not address the disease process in the rest of the coronary tree, and it does not remove the need for the medicines that protect both the stent and the arteries around it. NHS guidance is explicit that lifestyle change and medication continue after the procedure.

Myth: feeling well means the medicine has done its work. Antiplatelet therapy produces no sensation when it is working. The absence of symptoms says nothing about whether the stent struts are covered yet; that timeline runs on the body’s schedule, not on how you feel.

Myth: the second medicine is the important one, so aspirin can slide. As discussed above, aspirin carries the long-term protection. Dropping it because it seems ordinary removes the medicine intended to outlast all the others.

Myth: a blood thinner for atrial fibrillation covers the stent too. Anticoagulants and antiplatelets act on different parts of the clotting process. One does not stand in for the other, which is why some people are prescribed both.

Myth: bruising means the dose is too high. Easy bruising is the expected footprint of blunted platelets. It is worth reporting, but on its own it is not evidence of a problem and certainly not a reason to skip tablets.

Myth: it is safer to stop before the dentist, just in case. Most dental work proceeds safely on antiplatelet therapy. An unplanned interruption is the riskier choice.

Myth: a natural blood thinner such as fish oil can replace the prescription. No supplement has been shown to protect a coronary stent. Presenting one as a substitute is not supported by evidence, and the combination may increase bleeding without adding protection.

The common thread is that the medicines are quiet and the danger is silent. Neither announces itself, which is why the written plan from the cardiology team, not intuition, should govern what happens next.

Questions to ask your care team about your antiplatelet plan

A good consultation leaves you knowing not only what to take but why, and what to do when life intervenes. These questions tend to surface the answers that matter most. Write the responses down; the details fade faster than you expect.

• Which medicines on my list are protecting the stent, and which are for other reasons such as blood pressure or cholesterol?
• How long is the second antiplatelet planned for in my case, and what factors led to that length?
• Who will review the duration, and when? Will that be at a set appointment or triggered by something?
• What should I do if I miss a dose, and how late is too late to take it?
• If I run out unexpectedly, who do I contact, and is there an arrangement for urgent supply?
• Which everyday painkillers are safe for me, and which should I avoid?
• Are there any supplements I currently take that I should stop or discuss?
• If a dentist, surgeon or endoscopy unit asks me to stop a medicine, who should they speak to, and do you have written advice I can carry?
• What bleeding is expected, what should prompt a phone call, and what should send me to emergency care?
• Do I need a medicine to protect my stomach while on dual therapy?
• Should I carry a card or alert stating that I have a stent and take antiplatelet medicine?
• What symptoms after the procedure would suggest a problem with the stent itself rather than a side effect of the tablets?

One further question is worth asking even if it feels premature: what is the plan when the second medicine finishes? Knowing that aspirin continues, and that the team expects to see you at that transition, removes the moment of uncertainty that otherwise arrives with the last box. The transition should feel like a scheduled handover, not a cliff edge.

When to call your doctor: red-flag signs after a coronary stent

Most days on antiplatelet therapy are unremarkable. The signs below are the exceptions, and they fall into two groups: signs that the stent or heart may be in trouble, and signs that bleeding has moved beyond the expected.

Call emergency services immediately for chest pain, pressure or tightness that resembles the symptoms that led to the stent, especially if it spreads to the arm, jaw or back, comes with sweating, nausea or breathlessness, or does not ease with rest. A blocked stent produces a heart attack, and minutes matter. Sudden severe headache, weakness or numbness on one side, difficulty speaking, or confusion also need emergency care, as do vomiting blood, passing black or tar-like stools or large amounts of fresh blood, and any bleeding that will not stop with firm, sustained pressure. Sudden collapse or fainting belongs in this group too.

Contact your cardiology team or doctor the same day if you notice blood in your urine, nosebleeds that recur or take a long time to stop, a rapidly enlarging or painful lump at the wrist or groin access site, new breathlessness that was not there before, a widespread rash, unusually heavy periods, or bruising appearing without any knock. Call, too, if you have vomited or had diarrhea for more than a day and are unsure whether the medicine has been absorbed, or if you have missed more than one dose and are not certain how to proceed.

Raise at your next appointment minor gum bleeding, small bruises, indigestion that is bothersome but not severe, and questions about interactions or supplements.

Two rules sit above all of these. Never stop the medicines on your own in response to a symptom; describe the symptom to the team and let them decide. And if a health professional outside cardiology suggests a pause, make sure your cardiology team is part of the conversation before anything changes. The stent cannot speak for itself. For a few months, that is your job and theirs, shared.

Frequently asked questions

How long is dual antiplatelet therapy after a stent usually continued?

The second antiplatelet medicine is commonly continued for around six to 12 months, with the longer end typical when the stent was placed during a heart attack, according to NHS and Mayo Clinic guidance. Aspirin usually continues indefinitely. The exact duration is set by the cardiology team based on the type of stent, why it was placed, and your individual bleeding and clotting risk, and it can be shortened or lengthened at their discretion.

What happens if I stop clopidogrel after a stent without asking my doctor?

Stopping early removes protection from the stent struts before the artery lining has covered them, which can allow a clot to form inside the stent and cause a sudden heart attack. The American Heart Association identifies premature discontinuation as a leading cause of stent thrombosis. If a side effect, supply problem or another clinician’s request makes you consider stopping, contact your cardiology team first; they can usually resolve the issue without interrupting cover.

Do I still need aspirin after a heart stent if I am taking another blood thinner?

In most cases, yes, unless your cardiology team has specifically said otherwise. Aspirin is usually the medicine that continues long term after the second antiplatelet finishes, protecting not only the stent but the rest of the coronary arteries. If you also take an anticoagulant for atrial fibrillation, the team will have chosen a specific combination and a schedule for stepping it down. Never drop aspirin because it seems ordinary; ask whether it is part of your long-term plan.

Antiplatelet vs anticoagulant: are they the same thing after a stent?

No. Antiplatelet medicines such as aspirin and P2Y12 inhibitors act on platelets and are the main protection for a coronary stent. Anticoagulants such as warfarin or direct oral anticoagulants act on the clotting proteins in plasma and are prescribed for conditions like atrial fibrillation or vein clots. One does not replace the other, which is why some people are prescribed both for a period, with the combination kept as short as the stent safely allows.

Is bruising a sign that my blood thinners after a coronary stent are too strong?

Usually not. Easy bruising, longer-lasting bruises and minor gum or nose bleeding are the expected footprint of antiplatelet medicines and do not on their own indicate a problem. Bruises appearing without any knock, blood in the urine, black stools, vomiting blood or bleeding that will not stop with pressure are different and need prompt medical attention. Report bruising at your follow-up, but do not skip or reduce tablets in response to it.

Can I have a tooth extracted while on antiplatelet medicine after a stent?

Most dental procedures, including extractions, can be performed without stopping antiplatelet medicines, according to NHS guidance. Dentists use local measures such as pressure, sutures and gauze to manage bleeding, and the risk of stopping the medicine is considered greater than the inconvenience of slower clotting in the socket. Tell your dentist about the stent and your medicines before the appointment, and if they suggest stopping anything, ask them to contact your cardiology team first.

What should I do if I miss a dose of my stent medication?

Follow the written instructions supplied with your medicine or contact your pharmacist or cardiology team the same day rather than guessing. Because platelet inhibition wears off over days, one missed dose is unlikely to remove protection, but the right action depends on which medicine it is and how late you realise. Repeated misses are the real concern. Setting a daily reminder and keeping a spare week of supply reduces the chance of gaps.

Can I take ibuprofen for pain while on blood thinners after a stent?

Non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen increase stomach irritation and bleeding risk when combined with antiplatelet medicines, and some may interfere with aspirin’s effect on platelets. They are generally best avoided unless your care team has approved them. Ask your pharmacist about alternatives for everyday pain. The same caution applies to combination cold and flu products, which sometimes contain these ingredients.

Why does a drug-eluting stent need longer protection than a bare-metal one?

The coating on a drug-eluting stent slowly releases a medicine that discourages scar tissue from narrowing the channel, which is why these stents stay open longer. That same coating also slows the healthy artery lining from growing over the metal struts, extending the period during which exposed metal can attract platelets. Antiplatelet therapy bridges that gap, and its planned duration reflects how long the team expects the sealing process to take.

Will I feel different when the medicine is working, or when the stent has healed over?

No. Antiplatelet medicines produce no sensation when they are working, and the process of the artery lining covering the stent is silent. Feeling well is not evidence that protection is no longer needed, and feeling unwell is not evidence that the medicine has failed. Duration is judged by the cardiology team using the type of stent, the reason it was placed and your risk profile, not by how you feel on a given day.

References

• NHS: Coronary angioplasty and stent insertion, recovery
• MedlinePlus: Antiplatelet drugs, P2Y12 inhibitors

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.